STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: LinkMed’s (STO:LMED) portfolio company IMED AB has entered into an agreement with Medarex, Inc. to enable IMED AB to develop and commercialize fully human monoclonal antibodies that have been generated by IMED using Medarex’s UltiMAb® technology.
